This company has shut down. AgeX Therapeutics is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup GraveyardAgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases.
AgeX Therapeutics has raised $36.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2023.
AgeX Therapeutics's investors include Juvenescence, Lineage Cell Therapeutics, KIZOO Technology Capital, Jim Mellon, IBS Capital.
AgeX Therapeutics is headquartered in Alameda, United States.
AgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases.
AgeX Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AgeX Therapeutics — Funding & Investors." VCBacked, July 21, 2023, https://www.vcbacked.co/company/agex-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). AgeX Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/agex-therapeutics
{{cite web |title=AgeX Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/agex-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated